Clinical trials
Hypercholesterolemia trials in Greece
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Active, not recruiting | 3 |
| Recruiting | 2 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 9 |
| Novartis Pharmaceuticals | 4 |
| Elpen Pharmaceutical Co. Inc. | 3 |
| AHEPA University Hospital | 1 |
| Aristotle University Of Thessaloniki | 1 |
| AstraZeneca | 1 |
| Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) | 1 |
| Harokopio University | 1 |
| Hellenic Atherosclerosis Society | 1 |
| Kastle Therapeutics, LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypercholesterolemia | 26 |
| Dyslipidemias | 8 |
| Hyperlipidemias | 6 |
| Cardiovascular Diseases | 5 |
| Homozygous Familial Hypercholesterolemia | 4 |
| Hyperlipoproteinemia Type II | 4 |
| Aortic Valve Stenosis | 2 |
| Atherosclerosis | 2 |
| Heart Failure | 2 |
| Coronary Artery Disease | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.